Iron Homeostasis In Neurodegeneration plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Iron homeostasis is critical for normal brain function, as iron is an essential cofactor for oxidative phosphorylation, neurotransmitter synthesis, and myelin production. However, dysregulated iron metabolism is a hallmark feature of multiple neurodegenerative diseases, including Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS). Iron accumulation in specific brain regions correlates with disease progression and severity, making iron homeostasis a key therapeutic target. [1]
Iron balance in the body is tightly controlled through hepcidin-mediated regulation: [2]
| Protein | Function | Brain Expression | [3]
|---------|----------|------------------| [4]
| Transferrin (TF) | Iron transport in blood and CSF | Produced in choroid plexus |
| Ferritin (FTL/FTH) | Iron storage | All neural cell types |
| DMT1 | Ferrous iron transporter | Neurons, oligodendrocytes |
| Ferroportin (FPN) | Iron export | Neurons, microglia, endothelial cells |
| Hepcidin (HAMP) | Systemic iron regulation | Limited brain expression |
| IRP/IRE system | Post-transcriptional iron regulation | Ubiquitous |
Parkinson's disease is characterized by dramatic iron accumulation in the substantia nigra pars compacta (SNpc), particularly in neuromelanin-containing dopaminergic neurons:
Dopaminergic neurons are particularly vulnerable to iron toxicity due to:
Iron accumulates in brain regions affected by AD pathology:
Ferroptosis, an iron-dependent form of non-apoptotic cell death, contributes to neuronal loss in AD:
| Agent | Mechanism | Clinical Status |
|---|---|---|
| Deferoxamine (DFO) | Binds Fe³⁺ systemically | Phase II trial (PD); mixed results |
| Deferasirox (DFX) | Oral iron chelator | Preclinical |
| Clioquinol | Cu/Zn chelator with effects on Fe | Phase II (AD) - slowed cognitive decline |
| PBT2 | Metal-protein attenuation | Phase II (AD, HD) - failed primary endpoints |
The study of Iron Homeostasis In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent publications advancing our understanding of this mechanism:
Iron homeostasis and neurodegeneration in the ageing brain: Insight into ferroptosis pathways. (2024) — Ageing Res Rev PMID:39515619
Fueling neurodegeneration: metabolic insights into microglia functions. (2024) — J Neuroinflammation PMID:39551788
Understanding the Mechanism of Ferroptosis in Neurodegenerative Diseases. (2024) — Front Biosci (Landmark Ed) PMID:39206899
Loss of calcium/calmodulin-dependent protein kinase kinase 2, transferrin, and transferrin receptor proteins in the temporal cortex of Alzheimer's patients postmortem is associated with abnormal iron homeostasis: implications for patient survival. (2024) — Front Cell Dev Biol PMID:39669708
The Role of Glia in Wilson's Disease: Clinical, Neuroimaging, Neuropathological and Molecular Perspectives. (2024) — Int J Mol Sci PMID:39062788
Weinreb O, et al. Novel therapeutic strategies for Parkinson's disease: focus on iron. CNS Drugs. 2007. ↩︎
Ward RJ, et al. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurology. 2014. ↩︎
Muckenthaler MU, et al. A Red carpet for iron metabolism. Cell. 2017. ↩︎
Belaidi AA, Bush AI. Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics. Journal of Neurochemistry. 2016. ↩︎